A Study of Ustekinumab in Pediatric Participants (U-POPS) With Juvenile Psoriatic Arthritis or Psoriasis

Conditions

Ustekinumab — DRUG
This study does not provide dosing instructions for ustekinumab but will engage participants who have been treated with ustekinumab by their corresponding HCPs independent of this study.

The purpose of the study is to evaluate pharmacokinetics (PK) of ustekinumab in juvenile psoriatic arthritis (jPsA) and pediatric psoriasis (PsO).

Experimental: Cohort 1: Juvenile Psoriatic Arthritis (jPsA)
Participants (aged greater than or equal to \[\>=\] 5 to less than \[\<\] 18 years) will receive ustekinumab at the dose and frequency as prescribed by their treating health care professional (HCP).
Experimental: Cohort 2: Pediatric Psoriasis (PsO)
Participants (aged \>=6 to \<18 years) will receive ustekinumab at the dose and frequency as prescribed by their treating HCP.

Serum Concentration of Ustekinumab [ Time Frame: Up to 16 weeks ]

Facility	City	State	ZIP	Site coordinators
Newport Huntington Medical Group	Huntington Beach	California	92648	-
Childrens Hospital Los Angeles	Los Angeles	California	90027	-
Northwestern University Feinberg School of Medicine Ann & Robert H Lurie Children's Hospital	Chicago	Illinois	60611-2991	-
Michigan Dermatology Institute	Waterford	Michigan	48328	-
Columbia University Medical Center	New York	New York	10032	-
Akron Children s Hospital	Akron	Ohio	44308	-
Cincinnati Children's Hospital Medical Center	Cincinnati	Ohio	45229	-
Medical University of South Carolina	Charleston	South Carolina	29425	-
Dell Children's Medical Center of Central Texas	Austin	Texas	78723	-
Pediatric Rheumatology Consultants of Austin	Austin	Texas	78757	-

By condition

By specialty

By research site